EGFR-IN-135 (compound 3d) is an EGFR inhibitor with IC50 of 0.086 µM. EGFR-IN-135 inhibits cell growth and arrests the cell cycle at S phase in breast cancer cell lines.

Physicochemical Properties

Molecular Formula	C12H14N4OS2
Molecular Weight	294.40
Storage	Powder-20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month
Shipping Condition	Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)

Biological Activity

References

[1]. Synthesis of S-alkylated oxadiazole bearing imidazo2,1-bthiazole derivatives targeting breast cancer: In vitro cytotoxic evaluation and in vivo radioactive tracing studies. Bioorg Chem. Published online November 2, 2024.

Solubility Data

Preparing Stock Solutions		1 mg	5 mg	10 mg
	1 mM	3.3967 mL	16.9837 mL	33.9674 mL
	5 mM	0.6793 mL	3.3967 mL	6.7935 mL
	10 mM	0.3397 mL	1.6984 mL	3.3967 mL

*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.